MedTrace Logo

Anecortave Acetate Risk Reduction Trial (AART)

NCT00332657 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2012-11-28

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of dry age-related macular degeneration (AMD) in patients who are at-risk for progressing to wet AMD.

Conditions

Interventions

DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

One 0.5 mL injection into the PJD at 6-month intervals for 42 months

DRUG

Anecortave Acetate Sterile Suspension, 60 mg/mL

One 0.5 mL injection into the PJD at 6-month intervals for 42 months

OTHER

Anecortave Acetate Vehicle

One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Terry Wiernas, PhD · Study Director

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332657 on ClinicalTrials.gov